ENERGIZE THE FIGHT.
Our Mito Champions
Need to Connect with Us?
Call the Support Line: (888) 900-6486
UMDF Statement on the FDA’s Elamipretide Decision
May 29, 2025 -- Earlier today, the U.S. Food and Drug Administration (FDA) decided against approval of elamipretide for use in patients impacted by the rare mitochondrial disease Barth syndrome. UMDF President and CEO Kristen Clifford issued the following statement:...
UMDF Cosigns Letter to HHS Urging Preservation of Federal Newborn Screening System
Ask the Mito Doc – May 2025; Q&A
Ask the Mito Doc - May 2025 Q&A All answers today are based on personal experience of the participants. As always, please consult your personal physician prior to taking any action.Ask the Mito Doc - May 2025: Mitochondrial Disease and Biorepositories - Why...